Overview
- The UK National Screening Committee issued a draft recommendation against population PSA screening, citing modelling and evidence that harms from overdiagnosis and overtreatment outweigh benefits.
- The draft supports biennial checks only for men aged 45–61 with confirmed BRCA1/2 mutations and declines a separate programme for Black men due to insufficient trial data.
- The committee opened a consultation and commissioned further modelling from Sheffield’s Scharr, with a final recommendation expected in March 2026 and Wes Streeting set to weigh submissions.
- Major studies are progressing to close evidence gaps, including the £42m TRANSFORM programme testing fast MRI, PSA and genetic approaches, with initial results from up to 16,000 men expected in two to three years, alongside a newly launched two‑year trial.
- Political pressure continues as 125 MPs delivered a letter urging targeted screening for high‑risk groups, citing data on mortality reduction and safety gains from MRI‑before‑biopsy pathways.